Sarepta Therapeutics
SRPT
426 hedge funds and large institutions have $11.2B invested in Sarepta Therapeutics in 2023 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 151 increasing their positions, 134 reducing their positions, and 52 closing their positions.
35% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 52
13% more repeat investments, than reductions
Existing positions increased: 151 | Existing positions reduced: 134
10% more capital invested
Capital invested by funds: $10.2B → $11.2B (+$996M)
4% more funds holding
Funds holding: 411 → 426 (+15)
2.65% more ownership
Funds ownership: 89.66% → 92.32% (+2.7%)
5% more call options, than puts
Call options by funds: $489M | Put options by funds: $467M
8% less funds holding in top 10
Funds holding in top 10: 13 → 12 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$319M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$101M |
| 3 |
Two Sigma Advisers
New York
|
+$73.4M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$61.6M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$56.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$166M |
| 2 |
Janus Henderson Group
London,
|
-$145M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$85M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$82.9M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$68.4M |
SRPT Hedge Fund Activity: Q1 2023 in Review
426 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2023, worth a combined $11.2B — up 9.8% from $10.2B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new SRPT positions and 52 closed out — a net gain of 18 holders — while 151 added to existing stakes and 134 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $319M. The largest seller was Sands Capital Management, cutting an estimated $166M.
- 426 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2023, up from 411 in Q4 2022.
- Funds reported $11.2B of Sarepta Therapeutics stock for Q1 2023, up 9.8% quarter-over-quarter.
- 70 funds opened new Sarepta Therapeutics positions in Q1 2023 and 52 closed out, a net change of +18 holders.
- The largest Sarepta Therapeutics buyer in Q1 2023 was JP Morgan Chase, an estimated $319M added.
- The largest Sarepta Therapeutics seller in Q1 2023 was Sands Capital Management, an estimated $166M sold.
Based on aggregated 13F filings for Q1 2023.